Project: Development of a cost-effective vaccine against cervical cancer - a prophylactic approach
CERVI PRO aims to develop a cost-effective plastid-based prophylactic vaccine against cervical for high disease burdened developing countries such as Pakistan, from the start point of an existing prototype in tobacco. These vaccinea will be expressed in the form of L1 capsomeres directly coupled with Escherichia coli heat-labile enterotoxin subunit B (LTB) as adjuvant. This strategy makes simple and price reduced oral immunization possible delivered by a vaccine with enhanced immunogenicity.
| Acronym | CERVI PRO (Reference Number: 9817) |
| Duration | 01/08/2015 - 01/08/2018 |
| Project Topic | Biological Sciences / Technologies |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 3 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 21911 | BioEnergy GmbH & Consultant | Coordinator | Germany |
| 21912 | Geman Cancer Research Center | Partner | Germany |
| 21913 | Bionaturis Group | Partner | Spain |